BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Thomas Cluzeau, Guillaume Robert, Nicolas Mounier...
https://pubmed.ncbi.nlm.nih.gov/22577154/Actively Recruiting
Led by Centre Hospitalier Universitaire de Nice · Updated on 2025-03-19
250
Participants Needed
4
Research Sites
574 weeks
Total Duration
This research focuses on high-risk myelodysplastic syndromes MDS and acute myeloid leukemia with multilineage dysplasia AML-MD, conditions common in older adults with a median age of 71 years. The study aims to understand how the drug Azacitidine works and why resistance to it develops, particularly looking at its effects on cell death processes like apoptosis and autophagy. The investigation also explores new drugs that might reverse resistance to Azacitidine by targeting these cell death pathways. Participants in this observational study are adults aged 18 years or older with high-risk or intermediate 2 MDS or AML-MD who have undergone treatment with at least three to six cycles of Azacitidine. The study does not involve additional treatment but collects data to characterize molecular mechanisms of action and resistance. Researchers focus on hematological responses at three and six months and overall survival from the start of treatment and at death. During the study, participants clinical and molecular data related to their response to Azacitidine are observed and analyzed. The main outcomes include blood response measurements and survival tracking. The study is sponsored by the Centre Hospitalier Universitaire de Nice and began in 2010, with planned follow-up through September 2025. Participation involves regular monitoring without additional interventions, allowing researchers to evaluate treatment impact and resistance mechanisms over time.
CONDITIONS
Characterization of the Mechanisms of Resistance to Azacitidine
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centre Hospitalier Universitaire de Nice
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several months as per routine care
Participants who undergo routine care are observed to characterize mechanisms of resistance to Azacitidine in their condition.
Assessments at approximately 3 and 6 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Thomas Cluzeau, Guillaume Robert, Nicolas Mounier...
https://pubmed.ncbi.nlm.nih.gov/22577154/Centre Hospitalier Universitaire de Nice
Lead Sponsor